CLAIMS

1. A method of treating cancer in a host in need of treatment comprising administering to said host an anti-cancer effective amount of a compound of the formula

$$[\rightarrow 4)$$
- α -D-GlcNpAc($1\rightarrow 4$)- α -L-IdoAp2S($1\rightarrow]$ n

wherein GlcNpAc is 2-acetamido 2-deoxyglucopyranose, IdoAp is idopyranosyluronic acid and S is sulfate, and n is 1 to 1000.

- 2. The method of Claim 1 wherein n is 4 to 500.
- 3. The method of Claim 1 wherein n is 51 to 100.
- 4. The method of Claim 1 wherein n is 4 to 100.
- 5. The method of Claim 1 wherein n is 4 to 50.
- 6. A method of treating a host by inhibiting an increase in the volume or mass of a tumor in said host in need of treatment which comprises administering to said host a compound of the formula

$$[\rightarrow 4)$$
- α -D-GlcNpAc($1\rightarrow 4$)- α -L-IdoAp2S($1\rightarrow]$ n

wherein GlcNpAc is 2-acetamido 2-deoxyglucopyranose, IdoAp is idopyranosyluronic acid and S is sulfate, and n is 1 to 1000 in an amount effective to inhibit an increase in the volume or mass of a tumor.

- 7. The method of Claim 6 wherein n is 4 to 500.
- 8. The method of Claim 6 wherein n is 51 to 100.

- 9. The method of Claim 6 wherein n is 4 to 100.
- 10. The method of Claim 6 wherein n is 4 to 50.
- 11. A pharmaceutical composition comprising a compound of the formula

$$[\rightarrow 4)-\alpha$$
-D-GlcNpAc($1\rightarrow 4$)- α -L-IdoAp2S($1\rightarrow]$ n

wherein GlcNpAc is 2-acetamido 2-deoxyglucopyranose, IdoAp is idopyranosyluronic acid and S is sulfate, and n is 1 to 1000 in an amount effective to treat cancer in a host by inhibiting cancer growth in said host

- 12. The composition of Claim 11 wherein n is 4 to 500.
- 13. The composition of Claim 11 wherein n is 51 to 100.
- 14. The composition of Claim 11 wherein n is 4 to 100.
- 15. The composition of Claim 11 wherein n is 4 to 50.
- 16. A pharmaceutical composition comprising an amount of compound of the formula

$$[\rightarrow 4)-\alpha$$
-D-GlcNpAc($1\rightarrow 4$)- α -L-IdoAp2S($1\rightarrow]n$

wherein GlcNpAc is 2-acetamido 2-deoxyglucopyranose, IdoAp is idopyranosyluronic acid and S is sulfate, and n is 1 to 1000 that is effective in inhibiting an increase in the volume or mass of a tumor in a host in need of such inhibiting effect.

17. The composition of Claim 16 wherein n is 4 to 500.

- 18. The composition of Claim 16 wherein n is 51 to 100.
- 19. The composition of Claim 16 wherein n is 4 to 100.
- 20. The composition of Claim 16 wherein n is 4 to 50.
- 21. The use of a compound of the formula

$$[\rightarrow 4)-\alpha$$
-D-GlcNpAc($1\rightarrow 4$)- α -L-IdoAp2S($1\rightarrow]$ n

for the manufacture of a medicament useful for the treatment of cancer in a host in need of said treatment and administering said compound in an effective amount to said host wherein GlcNpAc is 2-acetamido 2-deoxyglucopyranose, IdoAp is idopyranosyluronic acid and S is sulfate, and n is 1 to 1000.

22. The use of a compound of the formula

$$[\rightarrow 4)-\alpha$$
-D-GlcNpAc($1\rightarrow 4$)- α -L-IdoAp2S($1\rightarrow]n$

for the manufacture of a medicament useful for inhibiting an increase in the volume or mass of a tumor in a host in need of said treatment and administering said compound in an effective amount to said host wherein GlcNpAc is 2-acetamido 2-deoxyglucopyranose, IdoAp is idopyranosyluronic acid and S is sulfate, and n is 1 to 1000.

- 23. The use of Claims 21 and 22 wherein n is 4 to 500.
- 24. The use of Claims 21 and 22 wherein n is 51 to 100.
- 25. The use of Claims 21 and 22 wherein n is 4 to 100.

26. The use of Claims 21 and 22 wherein n is 4 to 50.